Literature DB >> 20679474

Skin thickness progression rate: a predictor of mortality and early internal organ involvement in diffuse scleroderma.

Robyn T Domsic1, Tatiana Rodriguez-Reyna, Mary Lucas, Noreen Fertig, Thomas A Medsger.   

Abstract

OBJECTIVE: To examine the association of skin thickness progression rate (STPR) with mortality, and as a predictor of future internal organ involvement in an inception cohort of diffuse cutaneous systemic sclerosis (SSc) patients.
METHODS: Diffuse cutaneous SSc patients older than 16 years of age evaluated at the University of Pittsburgh within 2 years of the first evidence of skin thickening between 1980 and 2005 were eligible. The authors calculated the STPR on these patients, and examined the relationship of this variable to the development of early internal organ involvement and short-term mortality using logistic regression.
RESULTS: 826 patients were included in the analysis. Patients with a rapid STPR experienced significantly reduced short-term survival at 1 and 2 years from the time of first Pittsburgh evaluation (p=0.002). Patients with a rapid STPR were more likely to develop renal crisis within 1-2 years of follow-up. Rapid STPR was found to be an independent predictor of both mortality (OR 1.72; 95% CI 1.13 to 2.62; p=0.01) and 'renal crisis' (OR 2.05, 95% CI 1.10 to 3.85; p=0.02) within 2 years from first evaluation.
CONCLUSION: The STPR is an easy measure to perform at the time of initial evaluation for identifying those diffuse cutaneous SSc patients who are at increased risk of mortality and the development of renal crisis during the following 2 years.

Entities:  

Mesh:

Year:  2010        PMID: 20679474      PMCID: PMC3881170          DOI: 10.1136/ard.2009.127621

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  28 in total

1.  A survival study of patients with scleroderma diagnosed over 30 years (1953-1983): the value of a simple cutaneous classification in the early stages of the disease.

Authors:  A J Barnett; M H Miller; G O Littlejohn
Journal:  J Rheumatol       Date:  1988-02       Impact factor: 4.666

2.  Relationship between change in skin score and disease outcome in diffuse cutaneous systemic sclerosis: application of a latent linear trajectory model.

Authors:  Lynne Shand; Mark Lunt; Svetlana Nihtyanova; Mansour Hoseini; Alan Silman; Carol M Black; Christopher P Denton
Journal:  Arthritis Rheum       Date:  2007-07

3.  Mortality in systemic sclerosis (scleroderma).

Authors:  P Lee; P Langevitz; C A Alderdice; M Aubrey; P A Baer; M Baron; D Buskila; J P Dutz; I Khostanteen; S Piper
Journal:  Q J Med       Date:  1992-02

4.  Survival following the onset of scleroderma: results from a retrospective inception cohort study of the UK patient population.

Authors:  C Bryan; Y Howard; P Brennan; C Black; A Silman
Journal:  Br J Rheumatol       Date:  1996-11

5.  Prediction of survival in progressive systemic sclerosis by multivariate analysis of clinical features.

Authors:  J Wynn; N Fineberg; L Matzer; X Cortada; W Armstrong; J C Dillon; E L Kinney
Journal:  Am Heart J       Date:  1985-07       Impact factor: 4.749

6.  Predictors of survival in systemic sclerosis (scleroderma).

Authors:  R D Altman; T A Medsger; D A Bloch; B A Michel
Journal:  Arthritis Rheum       Date:  1991-04

7.  Different antibody patterns and different prognoses in patients with scleroderma with various extent of skin sclerosis.

Authors:  M Giordano; G Valentini; S Migliaresi; U Picillo; M Vatti
Journal:  J Rheumatol       Date:  1986-10       Impact factor: 4.666

8.  Clinical subsets, skin thickness progression rate, and serum antibody levels in systemic sclerosis patients with anti-topoisomerase I antibody.

Authors:  Achini Perera; Noreen Fertig; Mary Lucas; Tatiana S Rodriguez-Reyna; Paul Hu; Virginia D Steen; Thomas A Medsger
Journal:  Arthritis Rheum       Date:  2007-08

9.  Survival and causes of death in 366 Hungarian patients with systemic sclerosis.

Authors:  L Czirják; G Kumánovics; C Varjú; Z Nagy; A Pákozdi; Z Szekanecz; G Szucs
Journal:  Ann Rheum Dis       Date:  2007-05-22       Impact factor: 19.103

10.  Guidelines for clinical trials in systemic sclerosis (scleroderma). I. Disease-modifying interventions. The American College of Rheumatology Committee on Design and Outcomes in Clinical Trials in Systemic Sclerosis.

Authors:  B White; E A Bauer; L A Goldsmith; M C Hochberg; L M Katz; J H Korn; P A Lachenbruch; E C LeRoy; M P Mitrane; H E Paulus
Journal:  Arthritis Rheum       Date:  1995-03
View more
  57 in total

1.  Steroid-induced scleroderma renal crisis in an at-risk patient.

Authors:  Sebastian Miguel Toescu; Alex Mansell; Eoin Dinneen; Malcolm Persey
Journal:  BMJ Case Rep       Date:  2014-11-13

Review 2.  [Systemic sclerosis. Current classification and diagnosis of organ involvement].

Authors:  O D Persa; P Moinzadeh; N Hunzelmann
Journal:  Hautarzt       Date:  2015-08       Impact factor: 0.751

3.  Autologous hematopoietic cell transplantation for systemic sclerosis - a challenge for the Canadian health care system.

Authors:  Jan Storek; Andrew Daly; Sharon A LeClercq
Journal:  CMAJ       Date:  2017-05-01       Impact factor: 8.262

4.  Systemic sclerosis disease modification clinical trials design: quo vadis?

Authors:  Fabian A Mendoza; Lynette L Keyes-Elstein; Sergio A Jimenez
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-07       Impact factor: 4.794

Review 5.  My approach to the treatment of scleroderma.

Authors:  Ami A Shah; Fredrick M Wigley
Journal:  Mayo Clin Proc       Date:  2013-04       Impact factor: 7.616

6.  Autologous hematopoietic stem cell transplantation has better outcomes than conventional therapies in patients with rapidly progressive systemic sclerosis.

Authors:  N Del Papa; F Onida; E Zaccara; G Saporiti; W Maglione; E Tagliaferri; R Andracco; D Vincenti; T Montemurro; L Mircoli; C Vitali; A Cortelezzi
Journal:  Bone Marrow Transplant       Date:  2016-08-22       Impact factor: 5.483

7.  Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis.

Authors:  Dinesh Khanna; Daniel E Furst; Philip J Clements; Yannick Allanore; Murray Baron; Lazlo Czirjak; Oliver Distler; Ivan Foeldvari; Masataka Kuwana; Marco Matucci-Cerinic; Maureen Mayes; Thomas Medsger; Peter A Merkel; Janet E Pope; James R Seibold; Virginia Steen; Wendy Stevens; Christopher P Denton
Journal:  J Scleroderma Relat Disord       Date:  2017 Jan-Apr

8.  Indications for hospitalization and in-hospital mortality in Thai systemic sclerosis.

Authors:  Sittichai Netwijitpan; Chingching Foocharoen; Ajanee Mahakkanukrauh; Siraphop Suwannaroj; Ratanavadee Nanagara
Journal:  Clin Rheumatol       Date:  2012-12-08       Impact factor: 2.980

Review 9.  Determinants of mortality in systemic sclerosis: a focused review.

Authors:  Dilli Ram Poudel; Divya Jayakumar; Abhijeet Danve; Shiv Tej Sehra; Chris T Derk
Journal:  Rheumatol Int       Date:  2017-11-07       Impact factor: 2.631

Review 10.  Biomarkers in Scleroderma: Progressing from Association to Clinical Utility.

Authors:  Colin Ligon; Laura K Hummers
Journal:  Curr Rheumatol Rep       Date:  2016-03       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.